Medtronic evolut™ tavr platform outperforms surgery with sustained valve performance for low-risk patients at four years

Tct 2023: medtronic adds to the body of evidence for evolut tavr with late-breaking clinical trial data from the evolut low risk trial dublin and san francisco , oct. 24, 2023 /prnewswire/ -- medtronic plc (nyse:mdt), a global leader in healthcare technology, today announced four-year results from the evolut low risk trial.  the medtronic evolut™ transcatheter aortic valve replacement (tavr) system demonstrated exceptional outcomes and sustained valve performance, proven by significantly better hemodynamics than surgical aortic valve replacement (savr).
MDT Ratings Summary
MDT Quant Ranking